CN1819844A - Immunogen adhesion inhibitors and methods for their preparation and use - Google Patents

Abstract

Microbial adhesion inhibitors in the form of antibodies to poultry eggs, and methods of making and using the same are disclosed. The inhibitors function by substantially preventing the adhesion or attachment of colony forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is prepared by inoculating female birds with an immunogen, harvesting eggs containing antibodies to the immunogen, and separating the yolk and albumen from the eggshell. The egg yolk and egg white contents are administered to animals or humans by dispensing them directly or entraining them in air.

Description

Immunogen adhesion inhibitors and methods for their preparation and use

technical field

The present invention relates to microbial adhesion inhibitors in the form of avian egg antibodies, which are useful for substantially preventing the adhesion or attachment of immunogens causing colony-forming diseases in respiratory disease syndromes by inhibiting the adhesion of immunogens to the mucous membranes of animals Including host food animals, high value non-food animals, zoological animals, companion animals, laboratory animals or humans; and methods of making said adhesion inhibitors, and methods of using said inhibitors.

Background technique

A population of microorganisms forms very complex interactions within the airways of animals. The animals may be dairy cows, feeder cattle, pigs, poultry such as chickens and turkeys, and the like. Although the microbial communities vary between different animal groups, they are basically bacteria such as Pasteurellae, Mannhiemae and Haemophilus species, Mycoplasma bacteria, And respiratory virus groups, such as bovine respiratory fusion virus (bovine respiratory syncytial virus, BRSV), bovine viral diarrhea (bovine viral diarrhea, BVD) virus, parainfluenza virus (PI3), bovine infectious rhinotracheitis (infectious bovinerhinotrocheitus) , IBR) virus, porcine influenza virus (H ₁ N ₁ , H ₃ N ₂ ), fungi and parasites and combinations thereof. These microbial communities form respiratory condition-causing pathogens that can survive in the upper airways of healthy animals. Pasteurella and to a lesser extent Haemophilus and Mycoplasma species can cause bovine respiratory disease syndrome (BRDC) by invading the lower respiratory tract following nasopharyngeal endothelial injection. In dairy cows and feedlot herds, various stressful situations such as transport, weaning, viral infections, severe weather, weather changes, migration in feedlots, malnutrition and overcrowding can weaken the animal's immune system and body immunity ability to defend. This transfers most microorganisms from the nasopharynx to the lower airways inside the lungs. This leads to pneumonic respiratory disease syndrome, including shipping fever syndrome in cattle. Animal-to-animal transmission is generally through small airborne droplets or food or water contamination. Once the microorganisms have colonized the nasopharynx, aerosols during inspiration can cause bacteria to be sent down into the lower respiratory tract. This allows the microbial flora to come into contact with bronchial and alveolar cells and multiply causing pneumonia. Pulmonary infection can cause asymptomatic lesions but lead to decreased average daily gain. Animals may stop eating, rapidly become very sick and die within hours. Morbidity can be very high, and once one animal becomes ill the rest of the herd is susceptible to infection. This is the main concern of the feedlot. Similar patterns of spread occur in pig herds and in poultry groups such as chickens and turkeys. Current live vaccines have had limited success in protecting animals from the syndrome. This may partly result from a lack of immune protection in the nasopharynx. Although the respiratory viral populations debilitate the animal and reduce the host's immune response, strains that invade the lower respiratory tract (typically Mannhiema hemolytica or Pasteurella multocida) lead to disease in animals. Bronchopneumonia (BRD) of sickness and death. In bovine shipping fever pneumonia and enzootic pneumonia, the final common denominator of both types is the bacterial vector. Bovine respiratory disease (BRD) is a major cause of disease-related losses in feedlots today. Financial losses due to BRD include handling mortality, medications, veterinary and labor costs. The average cost of one treatment was an average of $8.80 per head. BRD heifers had a lower incidence of 37.9%. Never treated animals per head Net profit averaged over $11.48. Average daily gain was different for treated and untreated animals. Net profit averaged under $57.48 per head for treated animals. 20.6% of all food cattle deaths on feedlots due to BRD listed.

Porcine Respiratory Disease Syndrome is the major and similar type of disease affecting up to 90% of pig farmers. Mycoplasma hypopneumonia is a primary pathogen associated with a complex of secondary pathogens such as Pasteurella multocida types A and D and can cause clinical signs of hyperthermia or growth retardation. The combination of microorganisms can lead to increased severity and duration of swine pneumonia. Porcine reproductive and respiratory syndrome (PRRS) may be another major factor in swine pneumonia. This can cause severe reproductive disease with only minimal doses of viral PRRS strains. Common agents of porcine respiratory disease can include PRRS virus, porcine influenza virus (H ₁ N ₁ , H ₃ N ₂ ) and Mycoplasma hypopneumoniae as well as Haemophilus parasuis, Haemophilus porcine Haemophilus suis, Haemophilus pleuropneumonia, Pasteurella (Mannhiema) haemolytica, and Pasteurella multocida (types A and D) . It is difficult to estimate the total economic impact of the disease on the animal's health. Pneumonic lung injury can cause poor respiratory health in a herd and can affect up to 70% of pigs in a herd. A combination of viral vaccination and bacterial drug therapy is needed to help control the problem - the timing of vaccination is always important. Drugs must be administered at the appropriate time to minimize cost and harm to the animal.

Microorganisms such as Mycoplasma hypopneumoniae can cause an important chronic respiratory disease called "swine enzootic pneumonia" (SEP). These microorganisms alone can cause severe pneumonia in pigs and remain a significant threat to the swine industry.

Actinobacillus pleuropneumoniae causes "porcine pleuropneumoniae", causing severe economic loss and death. Although a vaccine has been developed, protection has not yet been demonstrated. In the past few years, 14 serotypes and 2 biotypes have been identified worldwide. Both growing and finishing pigs must be vaccinated to protect the herd.

The main impact of respiratory disease on swine producers is reduced feed intake, which leads to reduced growth. This results in poor uniformity of pigs, higher mortality, lower average daily gain and fewer pigs per litter. Producers reported respiratory disease in almost 14.4% of the herd. The cost of injectable vaccines and drugs increases while overall efficacy decreases. Reduced daily weight gain and antibiotics used to treat disease are estimated to cost the swine industry $4.67 billion annually. More than 39% of grow-finish pig deaths were attributed to pig respiratory disease.

current technology

Methods for the preparation of avian egg antibodies for use in the diagnosis or treatment of specific pathological conditions are known. No method has been proposed for the preparation of avian egg antibodies for inhibiting the colonization of microorganisms, especially of microorganisms and disease-causing immunogens, in the respiratory tract of animals.

Representative prior art patents include:

Polson, U.S. Patent No. 4,555,019

Stolle et al., US Patent No. 4,748,019

Tokoro, U.S. Patent No. 5,080,895

Carroll, U.S. Patent No. 5,196,193

Lee, U.S. Patent No. 5,367,054

Coleman, U.S. Patent No. 5,585,098

Stolle et al., U.S. Patent No. 5,753,268

Raun, US Patent No. 3,794,732 discusses the use of polyester antibiotics in ruminant diets to improve feed utilization in ruminants. This specifically illustrates the use of antibiotics as growth promoters in ruminants.

Raun, US Patent No. 3,947,836, discusses the use of certain antibiotic compounds when administered orally to ruminants to enhance animal feed utilization. Specifically, the animals developed rumen function to produce more propionate relative to acetate, thus improving feed utilization.

Ivy et al., US Patent No. 4,933,364, discuss alternative methods of promoting growth and increasing feed efficiency in feeding mammals. They propose the use of zinc antibiotics, which are added in an insoluble form to form zinc antibiotic complexes that improve the feed efficiency of feeding mammals. They refer to two patents, US Patent Nos. 3,501,568 and 3,794,732, which deal with monensin in great detail.

Other references to the use of additives such as monensin have mentioned the need for careful application of such materials as they are toxic to some animals (eg horses). Antibiotics that are not approved for use in dairy cows must be administered with caution. Furthermore, since monensin cannot be added to the syrup-based additions of traditional additives to cattle feed, feed intake is initially reduced. (Pate, E., "Ionophores Do Not Appear To Work In Molasses Supplements", ONA Reports, November 1966, p. 2, Florida Cattleman and Livestock Journal; Lona, R.P. et al., J.Anim.Sci.75( 1): 2571-2579, 1979).

Poison, U.S. Patent No. 4,550,019 relates to the manufacture and use of avian egg yolk antibodies for use in immunological preparations for passive immunization of animals, including humans, as immunological reagents for immunosorbent methods, particularly for quantitative analysis Testing, especially microanalysis for diagnostics, pathology, forensics and pharmacokinetic studies.

Stolle et al., U.S. Patent No. 4,748,018, relates to a method for passive immunization of mammals, wherein after first developing resistance to avian egg yolk antibodies in the mammal, by using different methods of administration under different conditions and using a combination of the described Antibodies against any of a variety of antigens are used in different compositions of antibodies.

Tokoro, U.S. Patent No. 5,080,895 relates to specific antibodies containing substances derived from eggs, methods for their preparation and use for the treatment of infectious or other diseases, and as additives to livestock and poultry food, cosmetics and medicines and in serum Use in the field of diagnostics. Although not explicitly stated, it is clear that the use of egg antibodies in feed is an easy way to treat enteric infections in livestock and poultry through oral administration of antibodies.

Carroll, US Patent No. 5,196,193 and divisional US Patent No. 5,443,976 relate to anti-venom compositions containing equine antibodies or avian egg yolk antibodies for neutralizing snake, spider, scorpion or jellyfish venom.

Lee, US Patent No. 5,367,054 relates to a method for extensive purification of egg immunoglobulins to reduce the number of somatic cells in lactating ruminant milk.

Stolle et al., US Pat. No. 5,753,268 relates to anti-cholesterol egg vaccines, methods for their preparation and use as dietary supplements for the treatment of vascular diseases in humans and other animals.

Contents of the invention

In general terms, the present invention relates to a method of preparing inhibitors of microbial adhesion that are administered to, for example, host food animals, high value non-food animals, zoological animals, companion animals, or humans to inhibit or substantially prevent bacterial colonization in the respiratory tract Adherence of the immunogen is formed by first vaccinating female birds at or about to reach egg-laying age with the specific immunogen of interest. The eggs produced by the birds are then harvested after a period of time sufficient for the birds to develop antibodies to the immunogen of interest. Egg yolk and egg white antibody-containing contents are separated from the shell. The antibody-containing content of the egg can be used directly, on a bulking agent or mixed with a carrier material. Antibodies can be incorporated into a liquid, mixed in lick basins, sprayed or sprayed into the environment with animals. Egg antibody adhesion inhibiting substances can be stored or shipped as needed.

Egg contents incorporating antibodies specific for the immunogen of interest can be administered to animals or humans by distributing the antibody material directly or entraining the antibody material in air. Substances can be introduced into the nasopharynx of animals by direct injection with a syringe or by spraying. The substance can be administered directly via a syringe or via intranasal inoculation. Aerosol mixtures can be prepared and administered to the animal's head and upper nostrils. Another option is to mix the substance with a carrier and dose it as a "topping" of the feed. Specific needs can be met by adding the substance to water and allowing animals or humans to drink the resulting solution. The active substance can be delivered by adding it to loose licks or feed baskets. A gelatinous mixture can be made using normal animal feed mixtures and poured into "licking pots" (feed additive bulk pots). Other delivery systems can be used to deliver the active substance to the respiratory tract.

Detailed ways

The present invention is based on a method of inhibiting the ability of colony-forming microorganisms, such as Pasteurella (Pasteurella) Mannhiema) haemolytica), Pasteurella multocida (P. multocida) and Haemophilus somnus (Haemophilus somnus), swine influenza virus (Swine influenza), Mycoplasmabovis or Mycoplasma hyopneumoniae (M hypopneumoniae) ). The inability of microbes to form colonies enables animals to mount immune defenses when exposed to stress-inducing environments. As a result, these animals developed fewer lung-respiratory diseases, including shipping fever, which resulted in high mortality in infected animals (Fig. 1)

All mammals and birds offer a similar type of protection, which provides an immediate immune response to their very young offspring until they acquire the ability to produce autoantibodies. More specifically known as passive antibody protection, this defense mechanism is passed on to young mammals through the placenta, breast milk, or both. However, hatchlings receive their passive antibody protection through antibodies stored in the eggs in which hatchlings develop from the embryonic stage. In particular, birds have the ability to "load" their eggs with very large amounts of enriched antibodies present in the maternal serum when their eggs are formed. Additionally, avian antibodies are much more stable than mammalian antibodies and are more resistant to inactivation by digestion, especially under adverse conditions. Once immunized, the hen lays eggs with a unique IgY type of immunoglobulin in the yolk, while depositing common chicken IgM and IgA immunoglobulins in the albumin. Albumin helps against whole egg products and helps protect the avian antibodies. The avian IgY immunoglobulins in the yolk tightly associate, coat, coat and clear away the cell adhesion factors that attach themselves to their hosts. Albumin, IgM and IgA immunoglobulins increase the association of antibody-containing material in the mucus tissue of the airways, which provides a longer lasting effect of the antibody-containing material. IgM and IgA immunoglobulins have disulfide bonds that hold the molecules together and provide for larger antibody-containing molecules. These larger antibody-containing molecules are more effective in preventing adhesion of the target immunogen in the respiratory tract of animals or humans. Albumin is a protein that protects the activity of IgY immunoglobulins thereby increasing their active lifetime in the respiratory tract. In addition, a large number of antibodies placed in eggs are more specific to those antigens to which the mother was recently exposed and which primed the mother. All of these lead to the fact that poultry eggs are the most ideal source for the economical production of high-specificity and stable antibodies in large quantities. Although the present invention utilizes chickens to illustrate the production of avian antibodies, other birds including turkeys, ducks, geese, ostriches, emu, pheasants, pigeons, quail, etc., or combinations thereof, can also be used.

Specifically, groups of young hens, usually Rhode Island Reds, White Leghorns, sex-mates, are obtained on a schedule based on the amount and timing of the final desired product. Crosses (sex-linked hybrid crosses) or other breeds suitable for large egg size, high egg production and ease of handling will reach laying age in about 16-19 weeks, resulting in a stable and continuous production process. After a suitable period of about two to four weeks of isolation and acclimatization, each cohort enters a vaccination program with a rehydration proprietary formulation of a specific antigen (immunogen) to obtain an antibody. Cultures of microorganisms are commercially available, such as the American Type Culture Collection (ATCC). Such cultures can be used to isolate antigens. The antigens can be prepared as prepared immunogens and can be injected intramuscularly, but preferably subcutaneously. In about four to five weeks, the common eggs collected will contain high quantities of antibodies of the desired specificity in an easy-to-use and stable form. Throughout the laying period, the chicks can be revaccinated with the immunogen of interest to maintain high levels of antibodies.

A batch of eggs from a predetermined group of chicks is cracked, the contents are separated from the shells and mixed, and preferably pasteurized to eliminate potential pathogenic microorganisms in the chicks, and thus reduce potential contamination. Standard testing procedures such as ELISA, agglutination or the like are used to monitor antibody activity. A typical batch is then blended with batches from other chick groups at normal production levels to obtain a large amount of standard active ingredient. Egg antibody microbial inhibitor substances can be stored and transported on carrier materials such as soybean oil, boluses and/or tablets. The final antibody product may contain some type of innocuous additive such as dried whey or soybean hulls, distiller's grains, molasses, soybean or rice bran or the like to formulate with the feed, according to the needs and specifications of the formulator and end consumer . One egg produced and processed by the procedure described above will yield a sufficiently active and stable product to provide controlled protection against colonization of specific microorganisms for at least up to 140 to 160 doses. The method provides for the first time an economical, safe and effective way to control the resulting Microbiomes in respiratory diseases.

The immunogen adhesion inhibitors and methods of making and using the same generate immunogens specific for the listed microbial species. The immunogen is used to immunize egg-laying avian animals. The immunized hens will lay eggs that contain IgM and IgA type specific antibodies in the albumen and IgY type specific antibodies in the yolk. The eggs are collected and the material from the whole cracked egg is mixed with a carrier material such as syrup, soybean oil, DMSO, PBS buffer and vitamin E solution at an appropriate concentration. The solution is optimized so that it can be sprayed, sprayed, injected intranasally, gelled or used in top feeding and licking tanks. The protective substance can be sprayed on animals in pens or in feedlots during feeding, usually once in the morning and once in the evening. The number of sprays is determined by testing. Since the substance is non-toxic, it can be given as needed, and as much as is required for a given enclosure. The preferred method is direct intranasal injection by using a 1/2 dose spray per nostril, or by a combination of direct nasal spray plus top feed, lick chute, spray applicator.

The product is an all natural preparation containing specific avian antibodies to the immunogen of interest. While antibodies attach to the microbe's outer surface cell walls, cell adhesion factor receptors, pili or pillar structures, and envelopes or viral capsids, these antibodies will not allow the microbe to attach to the mucosa. The microorganisms will not be able to reproduce or form colonies. This stops the microbes from moving down the airways and removes their ability to cause lower respiratory disease. By spraying the substance, the mist will coat the nasopharynx and prevent the spread of bacteria, viruses or other microorganisms in the droplets. The mist will also cover feed and water in the area, thereby blocking the ability of microbes to spread between animals. The method of the present invention results in a substantial reduction in animal disease and mortality in feedlots and pens without the use of antibiotics.

By reducing the respiratory microbiota, you can reduce lung damage, reduce secondary infections, improve daily gain, improve performance, increase feeding efficiency and reduce costs. Controlling pneumonia in animals will improve growth performance and quality of life, and reduce the potential spread of respiratory microorganisms. Similar examples are available in companion animals or humans. It is evident that many modifications and variations of the invention as set forth above may be made without departing from the spirit and scope thereof. The specific embodiments described are given by way of example only, and the invention is limited only by the appended claims.

The most successful colony-forming microorganisms, bacteria, viruses, parasites, etc., contain a large number of different types of molecules called "adherins (or intimins)" on their surfaces to which they adhere very tightly One or more types of specific molecules that are part of each surface of the host. Adhesion Inhibitor is an avian antibody with very high specific activity that binds very tightly, coats, coats, and clears these cell adhesion factors adapted to a very unique chemical structure The lock and key types attach themselves to their hosts. Avian IgY immunoglobulins in the yolk tightly bind, coat, cover, and eliminate cell adhesion factors that attach themselves to the host. Albumin, IgM and IgA immunoglobulins increase the incorporation of antibody-containing substances in mucous tissues of the airways, which provides longer-lasting effects of antibody-containing substances. IgM and IgA immunoglobulins have disulfide bonds that hold the molecules together and provide for larger antibody-containing molecules. These larger antibody-containing molecules are more effective in preventing adhesion of the target immunogen in the respiratory tract of animals or humans. Albumin is a protein that protects the activity of IgY immunoglobulins thereby increasing their active lifetime in the respiratory tract. In addition to said direct attack, the components of the complement system contained in most biological fluids (such as blood, lymph, saliva, tears and to some extent intestinal secretions) regard antibody attachment as a defense of many types active triggers. Thus, specific antibody attachment and coating is combined with the highly likely operation of many other cellular defense systems to rapidly achieve chemical inactivation and ultimately destruction of the target microorganism.

The present invention is further illustrated by the following examples:

                 Example 1: Selection of Laying Poultry Hens

Breeds of laying hens vary with needs and uses. Any laying bird hen can be vaccinated, including chicks, turkeys, ducks, geese, pigeons, quail, ostriches, emus or any other bird. Common breeds of laying hens are preferred, and are usually chosen based on the number of eggs laid per year, egg size and housing comfort. Lowe Island Reds, White Leghorns, and RedSex Linked hybrids were the animals selected based on egg size (Large to Extra Large, 50-65gm) and used in the immunization protocol. Ease of handling the animals and egg size and consistency were observed, as well as, the number of eggs laid per hen per year. Although any poultry layer hen can be used, these chickens have proven to be the best considering cost and ease of use. The White Leghorn, W98 hybrid had the best consistency and produced a greater number of eggs per animal. These animals produce large to jumbo grade eggs (50-65gm) and produce up to 300 eggs per hen per year.

Example 2: Preparation of PM antigen for immunogen

Pasteurella Multicoda (ATCC 15743) was used as a model bacterium. The microorganisms were isolated from cattle. The ATCC method used to rehydrate the stock is as follows. Bacteria were rehydrated in 1.0 ml of TSB. Brain Heart Infusion (BHI, Acumedia) was used to stimulate PM antigens on bacteria. The stock TSB was inoculated into BHI broth and incubated at 37°C for 18-24 hours. This stimulates the development of somatic and attached antigens on the bacteria. Inoculate the flask containing the BHI broth with the BHI broth broth. While stirring slowly, the flask was incubated at 37°C. Blood agar plates were streaked to isolate colonies for morphology determination. Good growth was seen after 22 hours. The flasks were combined and the resulting material was harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. Harvest products were collected in test tubes. Density was checked using spectrophotometer counts and McFarland turbidity standards. The material was diluted to approximately 1 x 10 ⁹ /ml. Add four percent (4%) sodium deoxycholate (sodium deoxycholate) (Difco) solution at a ratio of 1:1 to the culture medium in 0.9% sterile saline (Herzberg, 1972), and incubate at room temperature (22°C to 24°C) for about 18 hours. The material is centrifuged to remove intact cells. The supernatant can be used as a stock for PM antigen. The dry weight was determined to be approximately 14.9 mg/ml. The product was diluted to 1 mg/ml in sterile PBS (pH 7.4) for PM immunogens.

             Example 3: Preparation of PH antigen for immunogen

Stock P. Haemolytica (ATCC 14000) was used as stock for PH antigen. Microorganisms isolated from cattle. Follow ATCC method for rehydration stock. Bacteria were rehydrated in 1.0 ml of TSB. Brain heart infusion (BHI, Acumedia) was used to stimulate PM antigens on bacteria. Inoculate stock TSB in BHI broth and incubate at 37°C for 18-24 hours. This stimulates the development of somatic and attached antigens on the bacteria. Inoculate the flask containing the BHI broth with the BHI broth broth. While stirring slowly, the flask was incubated at 37°C. Good growth was seen after 22 hours. Colonies were isolated by streaking blood agar plates to determine morphology. Flasks were combined and material was harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. Harvest products were collected in test tubes. Density was checked using spectrophotometer counts and McFarland turbidity standards. The material was diluted to approximately 1 x 10 ⁹ /ml. Add four percent (4%) sodium deoxycholate (Difco) solution in a 1:1 ratio to the culture medium in 0.9% sterile saline (Herzberg, 1972), and incubate at room temperature (22°C to 24°C) Stirring was continued for about 18 hours. The resulting material was centrifuged to remove intact cells. The supernatant can be used as a stock for pH antigen. Determine the dry weight. The product was diluted to 1 mg/ml in sterile PBS (pH 7.4) for pH immunogens.

Example 4: Preparation of HS antigen for immunogen

The stock Haemophilus sommus (ATCC 43626) was used as the stock bacterial culture solution for the HS antigen. Microorganisms isolated from cattle. Follow ATCC method for rehydration stock. Bacteria were rehydrated in 1.0 ml of TSB. ATCC medium (ATCC medium): 814GC medium is used to stimulate HS antigen on bacteria. Inoculate stock TSB in 814GC medium and incubate for 18-24 h at 37 °C and 5% _CO2 . This stimulates the development of somatic and attached antigens on the bacteria. Good growth was seen after 22-48 hours. Blood agar plates were streaked for isolation of colonies to determine surface morphology. Flasks were combined and material was harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. Harvest products were collected in test tubes. Density was checked using spectrophotometer counts and McFarland turbidity standards. The material was diluted to approximately 1 x 10 ⁹ /ml. Add four percent (4%) sodium deoxycholate (Difco) solution in a 1:1 ratio to the culture medium in 0.9% sterile saline (Herzberg, 1972), and incubate at room temperature (22°C to 24°C) Stirring was continued for about 18 hours. The resulting material was centrifuged to remove intact cells. The supernatant can be used as a stock for HS antigen. Determine the dry weight. The product was diluted to 1 mg/ml in sterile PBS (pH 7.4) for use in the HS immunogen.

Example 5: Preparation of HSa antigen for immunogen

The stock Haemophilus suis (ATCC 19417, H. parasuis) was used as the stock for the HSa antigen. Isolation of microorganisms from pigs. Follow ATCC method for rehydration stock. Bacteria were rehydrated in 1.0 ml of TSB. ATCC Medium 5129: Haemophilus test medium for stimulation of HSa antigen on bacteria. Inoculate stock TSB in #5129 Broth and incubate at 37°C for 24-48 hours. This stimulates the development of somatic and attached antigens on the bacteria. Inoculate a flask containing #5129 broth or a plate containing #814 medium with the stock broth. Incubate the flask at 37 °C and 5% _CO2 . Good growth was seen after 48 hours. Blood agar plates were streaked for isolation of colonies to determine surface morphology. Flasks were combined and material was harvested using centrifugation and sterile saline (0.9%) at approximately 3000 rpm for 30 minutes. Harvest products were collected in test tubes. Density was checked using spectrophotometer counts and McFarland turbidity standards. The material was diluted to approximately 1 x 10 ⁹ /ml. Add four percent (4%) sodium deoxycholate (Difco) solution in a 1:1 ratio to the culture medium in 0.9% sterile saline (Herzberg, 1972), and incubate at room temperature (22°C to 24°C) Stirring was continued for about 18 hours. The resulting material was centrifuged to remove intact cells. The supernatant can be used as a stock for HSa antigen. Determine the dry weight. The product was diluted to 1 mg/ml in sterile PBS (pH 7.4) for use with the HSa immunogen.

        Example 6: Preparation of ELISA plates using PH, PM, HS and HSa antigens

                                             Used to monitor antibodies in laying hens and feed

PH, PM, HS and HSa ELISA: 96-well assay plates (flat bottom Costar) were coated with various concentrations of antigen (10 μg-200 μg/ml) at 100 μl/ml in carbonate buffer (pH 9.6). Plates were incubated between 22°C and 37°C for up to 18 hours. The wells were evacuated to prevent cross-contamination. Plates were blocked with 390 μl per well of 0.5% BSA and incubated at 37° C. for 1 hour. Plates were coated with positive or negative reference columns for control. Plates were washed once with wash buffer containing ^{Tween ™} 20. Add 100 μl per well of the diluted sample to duplicate wells and incubate at 37°C for 1 hr. Goat anti-chicken IgG conjugate with horseradish peroxidase (Kirkegard and Perry Laboratories; 1:1000 to 1:3000) was added. After 1 hour of incubation, substrates (TMB, KPL) were added according to the manufacturer's instructions, and after 10 minutes the reaction was stopped by 0.1 M phosphoric acid. The optical density of the wells was measured with a Dynatech ELISA Reader at 450 nm and the information was recorded for further data analysis.

Example 7: Analysis of individual eggs and serum over time

Eggs are selected at various times during the immunization period to monitor antibody responses to specific antigens. Selected chickens were monitored on day 0 and continued on a monthly basis after the fourth month. Whole eggs were collected from their shells, and a 1 ml sample was taken. The samples were then buffer extracted for analysis of antibody content. Analysis was performed using standard ELISA for PH, PM, HS and HSa immunogens. Subtract negative readings from OD readings.

Example 8: Immunization of Chickens with PH Immunogen

Inject the PH immunogen prepared by injecting a white Legion hen, which is about 19 weeks old, into laying hens. Four weekly injections (500 μg, 100 μg, 200 μg and 250 μg) were given. Two weeks after the last start of injection, serum samples were collected. If additional doses are required, add 100 μg each time (every 6 months). Within four weeks, all hens produced excellent antibodies in their eggs. EILSA pH average readings were 1.00 OD for a 1:10,000 dilution and 0.265 OD for a 1:50,000 dilution.

Example 9: Immunization of Chickens with PM Immunogen

A white Legion hen, a laying hen about 19 weeks old, was injected with the PM immunogen prepared. Four weekly injections (500 μg, 100 μg, 200 μg and 250 μg) were given. Two weeks after the last start of injection, serum samples were collected. If additional doses are required, add 100 μg each time (every 6 months). Within four weeks, all hens produced excellent antibodies in their eggs. EILSA PM average readings were 1.42 OD (for 1:10,000 dilution) and 0.68 OD (for 1:50,000).

Example 10: Immunization of Chickens with HS Immunogen

A white Legion chicken, a laying hen about 19 weeks old, was injected with the HS immunogen. Four weekly injections (500 μg, 100 μg, 200 μg and 250 μg) were given. Two weeks after the last start of injection, serum samples were collected. If additional doses are required, add 100 μg each time (every 6 months). Within four weeks, all hens produced excellent antibodies in their eggs. EILSAHS mean readings were 0.95 OD (for 1:10,000 dilution) and 0.250 OD (for 1:50,000).

Example 11: Immunization of Chickens with HSa Immunogen

A white Legion chicken, a laying hen about 19 weeks old, was injected with the HS immunogen. Four weekly injections (500 μg, 100 μg, 200 μg and 250 μg) were given. Two weeks after the last start of injection, serum samples were collected. If additional doses are required, add 100 μg each time (every 6 months). Within four weeks, all hens produced excellent antibodies in their eggs. EILSA HSa average reads were 1.40 OD for the 1:10,000 dilution and 0.576 OD for the 1:50,000 dilution.

              Example 12: Preparation of whole egg reagent for raw materials

Selected hens were combined from the cohort of all four immunogens for the production of batches of whole egg reagents. Sterling (US Patent No. 5,753,228) has an excellent review on egg selection and its storage. The eggs were randomly arranged and the shells were removed. Whole eggs were mixed well and pasteurized using standard conditions (60°C (140°F) for 3.5 minutes) (Charley, H. and C. Weaver, 3rd ed., Foods: a scientific approach, Merril-Prentice Hall , p. 350, 1998). After pasteurization, samples were tested for activity and stored at 4°C until dry, or sprayed onto carriers. 250 μl samples were analyzed.

Examples of ELISA results are as follows:

Pasteurized Whole Eggs: PM, PH, HS, HSa Blend

Immunogen Dilution O.D. PM 500 0.532 PM 2500 0.113 pH 500 0.466 pH 2500 0.115 HS 500 0.338 HS 2500 0.128 HSa 500 0.588 HSa 2500 0.155

                 Example 13: Antibody Activity Analysis of Feed Additives

Three batches of samples of the material were collected. Samples were analyzed for pH, PM, HS, HSa immunogens using an ELISA system to monitor activity after pasteurization and storage. A good antibody response was recorded after whole egg batch processing. The data from the three batches of the Example 20 production method are shown in the table below:

Batch Material: Liquid Pap immunogen SNR Haemophilus immunogen SNR Batch 1 0.347 5.32 0.111 2.68 Batch 2 0.188 2.92 0.175 2.93 Batch 3 0.272 2.98 0.138 1.91

Example 14: Testing feedlot cattle

A herd of 222 calves from 2 different sources was transported to Idaho. 109 calves were treated on day 0 and 113 on day 2. All calves receive normal vaccinations and treatments that include antibiotics designed to reduce disease pressure and improve average daily gain and feed efficiency. Half of the cohort received the substance by intranasal administration. Inject the dose directly into the nostril (1.5cc/nostril: 3ml total). The animals were tagged and monitored for 35 days. Keep all cattle in the same pen. N=111 in the test group and N=111 in the control group. The following results were observed:

Control group (n=111) Test group (n=111) number percentage number percentage sent to hospital 20 18 7 6 Those who are treated for respiratory diseases 19 17 7 6 deceased 3 3 0 0 Death due to respiratory disease 2 2 0 0 Retreater 5 3

Example 15: Testing Feedlot Cattle

Shipping a group of 165 barn calves for sale in the middle of summer. The calves were processed on day 0 and day 2. All calves receive normal vaccinations and treatments that include antibiotics designed to reduce disease pressure and improve average daily gain and feed efficiency. Half of the cohort received the substance by intranasal administration. Inject the dose directly into the nostril (1.5cc/nostril: 3ml total). The animals were tagged and monitored for 35 days. N=82 in the test group and N=83 in the control group. The following results were observed:

Control group (n=83) Test group (n=82) number percentage number percentage sent to hospital 36 47 twenty four 28 Those who are treated for respiratory diseases 36 43 twenty two 25 deceased 9 5 Death due to respiratory disease 8 4

Re-treatment 1X 14 12 Treatment 2X 10 4 Treatment 3X 4 3 Treatment 4X 3 2 Treatment 5X 6 1 treatment cost $1,291.44 $796.51 Average cost per treated animal $35.87 $30.64

Example 16: Testing feedlot cattle

Shipped 2 cohorts of calves to Idaho. The 77 calves in the first group were treated on day 0. Half of the group was treated as test group (n=39) and the other half as control (n=38). A second group of 78 underwent the same treatment on day 2. All calves receive normal vaccinations, deworming, grafts and treatments including antibiotics designed to reduce disease pressure and increase average daily gain and feed efficiency. The test group received the substance by intranasal administration. Inject the dose directly into the nostril (1.5cc/nostril: 3ml total). The animals were tagged and monitored for 35 days. Test group animals sent to the hospital received booster doses of substance and normal treatment each time they passed through the trough. Cows in the control group received normal treatment. N=77 in the test group and N=78 in the control group. The following results were observed:

Control group (n=78) Test group (n=77) number percentage number percentage sent to hospital 18 twenty three 13 17 Those who are treated for respiratory diseases 18 twenty three 13 17 deceased 1 1 Death due to respiratory disease 1 1 Re-treatment 1X 6 5 Treatment 2X 7 5 Treatment 3X 3 3 Treatment 4X 2 0

RES implementer 1 2 RES deceased 1 1 Mortality 1.28 1.30 treatment cost $691.49 $478.59 Average cost per head shipped $38.42 $36.81 Treatment cost per head in pen $8.87 $6.22

Example 17: Testing Weaned Calves

Four groups of calves were weaned at a rate of approximately 1000 to 2000 calves per week. The calves were handled in small groups. All calves receive normal vaccinations, deworming, grafts and treatments including antibiotics designed to reduce disease pressure and increase average daily gain and feed efficiency. The groups all received the substance by intranasal administration. Inject the dose directly into the nostril (1.5cc/nostril: 3ml total). The animals were tagged and monitored for 22 days. Group animals brought to the hospital received booster substances and normal treatment each time they passed through the trough. N=5000 in the test group. After 22 days, only 50 animals were excluded due to respiratory problems.

Example 18: Test the licking bowl

The manufacturing process of the licking bowl is extremely simple and straightforward. This fabrication example was made by adding the prepared wet material and distilling the concentrated slurry to the standard pot to adjust the moisture content up. We substitute dry matter and liquid matter to achieve the same moisture content as in standard pots that are often used to complete finished pots with similar characteristics.

An example of a total batch of licking bowls manufactured contained the following components:

Dried Distillers Grains with Solubles (DDGS) 1170 lbs

Corn Gluten Meal 1365 lbs

Wet Distilled Grain (Wet Block) 465 lbs

Vitamin and Mineral Premix 750 lbs

Magnesium Oxide 600 lbs

Mixed antibody 540 liters

Food Grade Syrup 10 Gallons

Mildewicide 6 lbs

The DDGS, corn gluten flour, wet block, mildew inhibitor, premix and magnesia were placed in a 5 ton mixer truck and mixed for 5 minutes. The mass and syrup are then added. It was mixed for 30 minutes. The resulting material weighed approximately 5,630 lbs. This mixture was unloaded through a side discharge chute into twenty-eight 200 lb plastic tubs and then compressed into a solid mass. The pots were then hardened for 48 hours to a very firm bark brown product with a slightly fermented sweetness (Figure 4).

In one experiment, a pot was placed near cattle in a pen with 197 600 lb steers. Cattle in the test feedlot were very interested in this substance. They visit the pots several times a day. Consumption was about 7.7 g/head/day. Consumption per head is expected to be higher if more pots are placed in the pen.

           Example 19: Development of Top Fertilizer

One of the main preparations can be used as a top fertilizer. Specific whole eggs were collected from hens immunized with PH, PM, HS and HAs antigens in the same amount (7-9 L in total). Add the whole egg mass to 2 L of PBS (pH 7.4), 4.5 L of syrup and 4 L of distilled water. Mix it well and add preservatives like food-grade vitamin E, vanilla, sodium benzoate, potassium sorbate, and sodium citrate to prevent microbial growth and extend shelf life. The total volume is 18L. The mixture was stirred to obtain a homogeneous solution. The mixture was then pasteurized in a Schlueter food pasteurizer. The resulting material was cooled and stored at 4°C until use.

This material can be poured on top of the feed as needed. Usually distributed every 7 days for a total of three applications.

Example 20: Development of substances for use in aerosols or sprays

One of the main formulations is available as an aerosol or spray. Specific whole eggs were harvested from hens immunized with PH, PM, HS and HAs antigens in the same amount (total 10 L). Add whole egg material to 6 L of PBS (pH 7.4) and 2 L of syrup. Mix it well and add preservatives like food-grade vitamin E, vanilla, sodium benzoate, potassium sorbate, and sodium citrate to prevent microbial growth and extend shelf life. The total volume is 18L. The mixture was stirred to obtain a homogeneous solution. The mixture is then pasteurized. The material was cooled and stored at 4°C until use.

This substance is sprayed directly onto the animal's head to form an aerosol. The substance can also be poured into a pressure gun, such as a water gun. Ranchers can carry these loading guns out of range, or inside the feedlot pen, and bring them directly to the cattle as needed. The substance can be sprayed directly into the nose of individual animals as desired. This becomes a very common application outside of the stated range. Usually distributed every 7 days for a total of three applications, or as needed.

Example 21: Animal testing of pigs

Groups of 77 feed pigs of approximately 60 lbs each were tested with the material prepared in Example 20 for top dressing. On days 0, 7, 14 and 21 the animals were given the substance as top dressing. The farm lost an average of 7.5% in the last 5 years due to respiratory syndrome, and more than 30% were medicated within the first 21 days of penning. During the 62-day testing period, all animals were in good condition, testing was completed ahead of schedule, and there were 0% losses and 0% drug treatment.

Example 22: Animal testing of pigs

Groups of 80 feed pigs of approximately 50 lbs were tested with the material for top fertilization prepared in Example 20 and taking into account stunted members of the group. On days 0, 7, 14 and 21 the animals were given the substance as top dressing. The average loss on this farm was 5% during the first 21 days due to respiratory syndrome, and more than 30% were treated with medication. These are animals that have not been handled well in the past. This is the average loss for farms over the past 5 years. During the 55-day test period, all animals were in good condition, the test was completed ahead of schedule, and better than in the past, with a loss of 1.25%, and 0% on medication.

Any microorganism that colonizes the nasopharynx of the respiratory tract of a host must have the ability to adhere or adhere to mucosal surfaces in order to reproduce. Respiratory pneumonia complex organisms such as Pasteurella multocida, Mannella haemolytica, Haemophilus somnus, swine influenza virus and mycoplasma bacteria are no exception. Microorganisms that can cause respiratory problems in animals or humans also include other microorganisms from the fungal and parasitic populations. The adhesion inhibitors of the present invention strongly impede adhesion and affect the accumulation base, thus preventing specific target microorganisms from colonizing, multiplying and moving down the respiratory tract and infecting the lower respiratory tract including the lungs. The product essentially provides the host with a specific antibody formulation that is not designed to treat any disease in the animal but merely to expel any microorganisms present via simple nasal injection and spray vehicle, top feed or lick basin And prevent any newly introduced microorganisms from contacting the upper respiratory tract. The adhesion inhibitor has no direct effect on the host itself, it is purely natural, does not leave any undesirable residues in the animal body at all, and therefore does not have any effect on the final food product. Furthermore, since the multiplication of microorganisms is prevented, it will disappear from the animal slime by natural degradation over time (eg 21-30 days), which eliminates a significant source of contamination in the feedlot. With proper management, the risk of cross-contamination of other animals throughout the facility is reduced and essentially eliminated. Similar applications can be developed in companion animals, zoological or non-food animals or humans. They also have respiratory problems.

It will be apparent that many modifications and variations of the invention described above can be made without departing from the spirit and scope of the invention. The specific embodiments described are given by way of example only and the invention is limited only by the appended claims. Embodiments claiming the specific characteristics or privileges of the present invention are as described above.

Claims (48)

1. A microbial adhesion inhibitor for administering to an animal to sufficiently prevent the adhesion of a target colony-forming immunogen in the respiratory tract of said animal, characterized in that it is produced by the following method: A. Inoculation of female birds at or about to reach egg-laying age with the target colony-forming immunogen; B. providing sufficient time to allow production of an antibody-containing content directed against said target colony-forming immunogen in eggs produced by said avian; C. Harvesting the poultry eggs produced by said poultry; D. Isolating the antibody-containing content of the avian egg from the eggshell. 2. The microbial adhesion inhibitor of claim 1, wherein said colony forming immunogen is known to reduce the ability of animals to utilize feed by causing respiratory disease. 3. microbial adhesion inhibitor according to claim 2, is characterized in that: described target bacterium colony forms immunogen from comprising Pasteurella multocida (P.Multocida), hemolytic Mannella (M.haemolytica) , Haemophilus somnus (H.somnus) and Haemophilus suis (H.suis) respiratory bacterial species. 4. microbial adhesion inhibitor according to claim 2, is characterized in that: described target bacterium colony forms immunogen from and comprises pleuropneumoniae mycoplasma (Mycoplasma pleuropneumoniae), hyopneumoniae (M.hypopneumoniae) and bovis mycobacterium (M. .bovis) respiratory bacterial species. 5. The method according to claim 1, wherein the antibody-containing content is derived from chicken, turkey, duck, goose, pheasant, emu, pigeon, ostrich, quail eggs or any combination thereof. 6. The microbial adhesion inhibitor according to claim 1, wherein said colony-forming immunogen is known to cause respiratory diseases in humans. 7. The microbial adhesion inhibitor of claim 1, comprising: mixing the antibody-containing content isolated from the egg with a carrier material. 8. microbial adhesion inhibitor according to claim 1, is characterized in that, comprises: A. mixing the antibody-containing content isolated from the egg; and B. Pasteurizing the combined antibody-containing content isolated from the egg to eliminate potential pathogenic microorganisms. 9. The microbial adhesion inhibitor of claim 8, comprising depositing said pasteurized mixture of antibody-containing content isolated from said egg on a carrier material. 10. The microbial adhesion inhibitor according to claim 9, characterized in that the carrier material is from the group of materials comprising soybean oil, molasses, evaporated cereals and sugar beet pulp. 11. The microbial adhesion inhibitor according to claim 1, wherein the target colony-forming immunogen is known to cause respiratory diseases in companion animals. 12. The microbial adhesion inhibitor of claim 1, wherein said target colony forming immunogen is known to cause respiratory disease in high value non-food animals such as horses, zoological animals and laboratory animals. 13. The microbial adhesion inhibitor according to claim 1, wherein the target colony-forming immunogen is from a respiratory virus species including porcine influenza virus (H1N1, H3N2). 14. The microbial adhesion inhibitor according to claim 1, characterized in that: the target colony-forming immunogen is derived from bovine respiratory fusion virus (bovine respiratory syncytial virus, BRSV), bovine viral diarrhea (bovine viral diarrhea, Respiratory virus species of BVD virus, bovine parainfluenza3 (BPI ₃ ) and infectious bovine rhinotracheitis (IBR) virus. 15. A microbial adhesion inhibitor for administration to food animals, characterized in that the microbial adhesion inhibitor sufficiently prevents the adhesion of the target bacterial colony-forming immunogen in the respiratory tract of the food animal, and contains a compound specific for the food animal. The target colony-forming immunogen antibody binds the egg content. 16. The microbial adhesion inhibitor according to claim 15, characterized in that the target colony-forming immunogen is known to reduce the animal's ability to utilize feed, thereby reducing average daily gain. 17. The microbial adhesion inhibitor according to claim 15, characterized in that the target colony-forming immunogen is from a respiratory virus species including porcine influenza virus (H1N1, H3N2). 18. The microbial adhesion inhibitor according to claim 17, wherein said target colony-forming immunogen is known to cause human respiratory syndrome. 19. The microbial adhesion inhibitor according to claim 15, characterized in that: the target colony-forming immunogen comes from a group comprising bovine respiratory fusion virus (BRSV), bovine viral diarrhea (BVD), bovine parainfluenza No. Respiratory virus species of type III virus (BPI ₃ ) and bovine infectious rhinotracheitis (IBR) virus. 20. A microbial adhesion inhibitor for promoting the growth of a food animal by reducing the respiratory stress response caused by a colony-forming immunogen present in the respiratory tract of the food animal, which Reduce the ability of colony-forming immunogens to reproduce by inhibiting the ability of colony-forming immunogens to adhere to the respiratory tract of the food animal, characterized in that: the colony-forming immunogen PRRS is produced by the following method: A. Vaccination of female birds at or about to reach laying age with P antigen from PRRS; B. providing sufficient time to allow for the production of antibodies against the P antigen from PRRS in the birds and the eggs they produce; C. Harvesting the poultry eggs produced by said poultry; D. Isolating the antibody-containing content of the avian egg from the eggshell. 21. The microbial adhesion inhibitor according to claim 20, wherein the antibody-containing content isolated from the egg is obtained by mixing a carrier material with the antibody-containing content of the egg of. 22. The microbial adhesion inhibitor according to claim 21, characterized in that the carrier material is from the group of materials comprising soybean oil, molasses, evaporated cereals and sugar beet pulp. 23. The method of claim 20, wherein the antibody-containing content is derived from chicken, turkey, duck, goose, pheasant, emu, pigeon, ostrich, quail eggs or any combination thereof. 24. The microbial adhesion inhibitor of claim 20, wherein said colony forming immunogen is known to cause respiratory disease in companion animals. 25. The microbial adhesion inhibitor according to claim 20, characterized in that said colony forming immunogen is known to cause respiratory disease in high value non-food animals such as horses, zoological animals and laboratory animals. 26. A method for reducing respiratory diseases in animals, which reduces the ability of immunogens to reproduce by inhibiting the ability of target bacteria to form immunogens and adhere to the respiratory tract of animals, characterized in that: the method comprises: A. Inoculation of female birds at or about to reach egg-laying age with the target colony-forming immunogen; B. providing sufficient time to allow the production of antibody-containing content directed against the target colony-forming immunogen in the egg produced by the avian; C. Harvesting the poultry eggs produced by said poultry; D. separating the entire contents of the harvested egg from the shell; E. mixing the contents separated from said harvested eggs; and F. Administering said mixed contents isolated from harvested eggs to said animal, whereby said antibody against a target colony-forming immunogen inhibits adhesion of said target colony-forming immunogen in the respiratory tract of said animal attached. 27. The method of claim 26, wherein the target colony-forming immunogen is from a respiratory bacterial species including Mycoplasma pleuropneumoniae, Mycoplasma hyopneumoniae and Mycobacterium bovis. 28. The method of claim 26, wherein the target colony-forming immunogen is derived from respiratory bacterial species including Pasteurella multocida, Mannella haemolytica, Haemophilus somnus, and Haemophilus suis . 29. The microbial adhesion inhibitor according to claim 26, characterized in that: the target colony-forming immunogen comes from a group comprising bovine respiratory fusion virus (BRSV), bovine viral diarrhea (BVD), bovine parainfluenza No. Respiratory virus species of type III virus (BPI ₃ ) and bovine infectious rhinotracheitis (IBR) virus. 30. The microbial adhesion inhibitor according to claim 26, characterized in that the target colony-forming immunogen is from a respiratory virus species including porcine influenza virus (H1N1, H3N2). 31. The method of claim 26, comprising: The combined separated contents of the harvested eggs are mixed with a carrier material. 32. The method of claim 31 , comprising: The mixture of contents separated from the harvested eggs is pasteurized to eliminate potential pathogenic microorganisms. 33. The method of claim 32, comprising: The pasteurized mixture of the contents separated from the harvested eggs is deposited on a carrier material. 34. The microbial adhesion inhibitor of claim 26, wherein the antibody-containing content of the egg is administered by spraying or injecting a substance having the antibody-containing content of the egg into animal feed . 35. The microbial adhesion inhibitor according to claim 34, wherein said material is from the group of materials comprising whey, syrup, PBS and soybean oil. 36. The method of claim 26, wherein said antibody-containing content is administered by spraying said antibody-containing content into an environment housing an animal. 37. The method of claim 26, wherein the antibody-containing content is administered by intranasally injecting the antibody-containing content into the animal. 38. The method of claim 26, wherein the target colony-forming immunogen is from a respiratory bacterial species including M. pleuropneumoniae, M. hyopneumoniae, and M. bovis. 39. The method of claim 26, wherein the target colony-forming immunogen is from a respiratory bacterial species including Pasteurella multocida, Mannella haemolytica, Haemophilus somnus, and Haemophilus suis . 40. The microbial adhesion inhibitor according to claim 26, wherein said target colony-forming immunogen is from a respiratory virus species including porcine influenza virus (H1N1, H3N2). 41. The microbial adhesion inhibitor according to claim 26, characterized in that: said target colony-forming immunogen comes from a group comprising bovine respiratory fusion virus (BRSV), bovine viral diarrhea (BVD), bovine parainfluenza No. Respiratory virus species of type III virus (BPI ₃ ) and bovine infectious rhinotracheitis (IBR) virus. 42. A method for producing a microbial adhesion inhibitor for administration to humans to inhibit the adhesion of a target colony-forming immunogen in the human respiratory tract, wherein the method comprises: A. Inoculation of female birds at or about to reach egg-laying age with the target colony-forming immunogen; B. providing sufficient time to allow the production of antibody-containing content directed against the target colony-forming immunogen in the egg produced by the avian; C. Harvesting the eggs produced by the poultry; D. separating the entire contents of the harvested egg from the shell; and E. Mixing the contents separated from the harvested eggs. 43. The method of claim 42, wherein said colony forming immunogen is known to cause respiratory disease in humans. 44. The method of claim 42, wherein the target colony forming immunogen is from a respiratory virus species including porcine influenza virus (H1N1, H3N2). 45. The method of claim 42, comprising: mixing said antibody-containing content isolated from said egg with a carrier material. 46. The method of claim 42, comprising: A. mixing said isolated antibody-containing content from said egg; and B. Pasteurizing the combined antibody-containing content isolated from the egg to eliminate potential pathogenic microorganisms. 47. The method of claim 46, comprising depositing the pasteurized mixture containing antibody content isolated from harvested eggs on a carrier material. 48. The method of claim 47, wherein the carrier material is from the group of materials comprising soybean oil, molasses, evaporated cereals and sugar beet pulp.